Arcellx Appoints Rami Elghandour as Chairman and Chief Executive Officer
January 26, 2021 16:00 ET
|
Arcellx, Inc.
GAITHERSBURG, Md., Jan. 26, 2021 (GLOBE NEWSWIRE) -- Arcellx, a privately held clinical-stage biopharmaceutical company developing adaptive and controllable cell therapies, today announced the...
Arcellx CART-ddBCMA Cell Therapy Demonstrates Deep and Durable Responses in the Treatment of Relapsed and Refractory Multiple Myeloma
December 07, 2020 10:00 ET
|
Arcellx, Inc.
- Company announces initial results in first-in-human trial utilizing novel synthetic binding domain - - 6/6 (100%) overall response rate (ORR) per International Myeloma Working Group (IMWG)...
Arcellx Announces Clinical Data to be Presented at the 62nd American Society of Hematology (ASH) Annual Meeting
November 05, 2020 09:30 ET
|
Arcellx, Inc.
Presentation to include clinical data from Arcellx’s ongoing Phase 1 study of CART-ddBCMA, a genetically engineered cell therapy utilizing the company’s novel synthetic binding domain for the...
Arcellx to Present at Jefferies Virtual Cell Therapy Summit
October 02, 2020 07:08 ET
|
Arcellx, Inc.
GAITHERSBURG, Md., Oct. 02, 2020 (GLOBE NEWSWIRE) -- Arcellx today announced that David Hilbert, Chief Executive Officer, will present at the following upcoming investor conference. Presentation...
Arcellx Announces EvansMDS Grant Awarded for Collaboration with Johns Hopkins and University of Colorado Researchers to Support Development of Arcellx ARC-sparX Platform Candidate ACLX-002
August 24, 2020 07:00 ET
|
Arcellx, Inc.
- Edward P. Evans Foundation funding initiative to support efforts toward clinical development of Arcellx candidate cell therapy in the treatment of myelodysplastic syndromes - GAITHERSBURG, Md.,...
Arcellx Presents Preclinical Data for ARC-sparX Platform Technology in Targeting CD123-Positive AML Tumors
June 22, 2020 09:00 ET
|
Arcellx, Inc.
GAITHERSBURG, Md., June 22, 2020 (GLOBE NEWSWIRE) -- Arcellx, a clinical-stage biopharmaceutical company developing novel, adaptive and controllable cell therapies for the treatment of patients with...
Arcellx to Present at Jefferies Virtual Healthcare Conference
June 02, 2020 07:00 ET
|
Arcellx, Inc.
GAITHERSBURG, Md., June 02, 2020 (GLOBE NEWSWIRE) -- Arcellx, a clinical-stage biopharmaceutical company developing novel, adaptive and controllable cell therapies for the treatment of patients with...
Arcellx to Present at the UBS Virtual Global Healthcare Conference
May 19, 2020 14:23 ET
|
Arcellx, Inc.
GAITHERSBURG, Md., May 19, 2020 (GLOBE NEWSWIRE) -- Arcellx, a clinical-stage biopharmaceutical company developing novel, adaptive and controllable cell therapies for the treatment of patients with...
Arcellx to Present Preclinical Data of its Novel ARC-sparX Platform Technology in Targeting HER2+ Solid Tumors at the 2020 American Society of Clinical Oncology Virtual Annual Meeting
May 13, 2020 17:01 ET
|
Arcellx, Inc.
GAITHERSBURG, Md., May 13, 2020 (GLOBE NEWSWIRE) -- Arcellx, a clinical-stage biopharmaceutical company developing novel, adaptive and controllable cell therapies for the treatment of patients with...
Arcellx to Present Preclinical Efficacy Data of the ARC-sparX Platform Technology at the 2020 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
April 29, 2020 13:24 ET
|
Arcellx, Inc.
GAITHERSBURG, Md., April 29, 2020 (GLOBE NEWSWIRE) -- Arcellx, a clinical-stage biopharmaceutical company developing novel, adaptive and controllable cell therapies for the treatment of patients...